Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Clinical trial NCT06575686 · SUSPENDED

Trial details

NCT number: NCT06575686
Sponsor: City of Hope Medical Center
Status: SUSPENDED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3a Follicular Lymphoma Refractory Grade 1 Follicular Lymphoma Refractory Grade 2 Follicular Lymphoma Refractory Grade 3a Follicular Lymphoma

Start date: 2025-03-11
Primary completion: 2028-07-16
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.